Latest News in the pharma Industry
Research & Development
Novartis receives positive CHMP opinion for Rydapt
23 Jul 2017
If approved, Rydapt would represent the first targeted treatment for newly diagnosed FLT3-mutated AML in the EU.
Read more
Catalent and academia on quest to better understand pediatric drug formulation and delivery challenges
20 Jul 2017
Goal of the collaboration is to identify therapies and diseases for which there is a high need for pediatric-friendly formulations.
Read more
Positive results from 12-month Phase III safety study of Revefenacin in patients with COPD
20 Jul 2017
These data, combined with positive results from two Phase III efficacy studies, support NDA filing planned for fourth quarter of 2017.
Read more
Onyx helps to accelerate TopiVert’s compounds to clinic
19 Jul 2017
With support from the CRO, TopiVert has been able to accelerate scale-up and produce GMP batches, which are now being used in clinical trials.
Read more
Shire expands broad monoclonal antibody research platform
18 Jul 2017
Shire obtains worldwide license to pursue development and commercialization of a novel, potentially differentiated, pre-clinical bi-specific antibody candidate for Hemophilia A.
Read more
Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation
18 Jul 2017
Array to advance preclinical program for autoimmune disorders; Amgen responsible for clinical development and worldwide commercialization.
Read more
Alzheon presents new data for ALZ-801 on novel MOA and long-term clinical efficacy at the AAIC
17 Jul 2017
Presentations highlight recent discovery of inhibition of formation of toxic beta amyloid oligomers and new insights for Precision Medicine approach for ALZ-801 targeting APOE4 carriers.
Read more
Ground-breaking preclinical data to be presented at AAIC 2017
16 Jul 2017
KalGene’s Alzheimer’s therapeutics candidate, licensed from the NRC (KAL-ABP-BBB), crosses the blood-brain barrier, and reduces amyloid-beta burden in a transgenic rat model after a 4-week treatment.
Read more
Novartis confirms 5-year data for Cosentyx reinforcing sustained efficacy and safety profile in psoriasis
16 Jul 2017
Cosentyx continues to demonstrate it can provide what psoriasis patients want - a life with clear skin.
Read more
Novartis CAR-T cell therapy CTL019 recommended for FDA approval
13 Jul 2017
A BLA for this indication is under FDA priority review; if approved, CTL019 could become first CAR-T cell therapy available.
Read more
FDA approves Blincyto to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia
12 Jul 2017
Blincyto is the first and only Bispecific T cell Engager (BiTE) immunotherapy to demonstrate superior overall survival versus standard of care chemotherapy.
Read more
Erytech collaborates with Queen’s University to advance product candidate for rare metabolic disorders
12 Jul 2017
The collaboration will leverage the expertise of Queen’s University and Erytech’s ERYCAPS platform technology.
Read more